NasdaqGS:CGONBiotechs
CG Oncology (CGON) Is Up 6.8% After Naming Biotech Veteran Jim DeTore CFO - Has The Bull Case Changed?
On April 13, 2026, CG Oncology, Inc. appointed Jim DeTore as Chief Financial Officer after he had served as Interim Principal Financial and Accounting Officer since November 2025 and previously held senior finance roles at several biotechnology companies, including Neurogastrx, Proteostasis Therapeutics, and Bluebird Bio.
This appointment adds long-tenured biotech financial leadership at a time when CG Oncology’s oncolytic immunotherapy program for bladder cancer is attracting increased...